Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility.
Quotient Clinical, a provider of early stage and drug development services, has been acquired by healthcare investor GHO Capital.
Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility. It employs over 280 staff and offers a range of support services, from study set-up to data analysis and reporting. Over 75% of its customers are in the U.S. or mainland Europe.
“We are delighted to be partnering with GHO Capital for the next phase of our growth,” said Mark Egerton, Chief Executive Officer of Quotient Clinical. “In the past few years, we have proven the benefits of Translational Pharmaceutics (the company’s own platform), and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.